Curcumin-mediated Modulation of T-bet and CD8+ T Cells: A Potential Anti-inflammatory Mechanism in Knee Osteoarthritis.

Ghoryani and colleagues at Iranian medical universities ran a secondary molecular analysis on RNA samples from a completed double-blind placebo-controlled trial of 30 knee osteoarthritis patients. Participants had taken 80 mg/day of nano-micelle curcumin or placebo for 3 months. The analysis measured TH1 and TH2 transcription factors, T-bet and GATA3, with real-time PCR, and tested associations with pain score (VAS), CRP, ESR and CD4+/CD8+ T cell percentages.

Curcumin reduced T-bet gene expression versus baseline and the reduction correlated with CD8+ T cell frequency. GATA3 did not change. The authors read this as curcumin modulating TH1-associated transcriptional programs.

Three caveats. This is a secondary analysis of a small trial, not a new clinical outcome. N=30 split across two arms gives very low statistical power for the correlations. And 80 mg/day of a nano-micelle form is far below the 500-1500 mg typical of curcumin trials, though nano-formulation changes bioavailability. For longevity readers: this is a mechanism paper in osteoarthritis, not evidence for any aging outcome. Curcumin's evidence grade stays C.

Curcumin administration significantly reduced T-bet gene expression compared to baseline and showed a positive correlation with the frequency of CD8+ T cells, while GATA3 expression remained unchanged.